IP Library › Granted Patent US 7,622,108
Granted Patent B2
US 7,622,108 · App. 11/208,873 · Granted Nov 24, 2009

Multi-lineage progenitor cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,622,108
App. No.
11/208,873
Granted
Nov 24, 2009
Kind
B2
Abstract

Fetal blood multi-lineage progenitor cells that are capable of a wide spectrum of transdifferentiation are described.

Claims (6)

1. A method of characterizing a population of multi-lineage progenitor cells (MLPC), said method comprising: a) providing a purified population of MLPC, wherein said MLPC are positive for CD9, CD13, CD29, CD44, CD73, CD90 and CD105, and negative for CD10, CD34, CD41, CD45, Stro-1, Stage Specific Embryonic Antigen-3 (SSEA-3) and SSEA-4; and b) assessing expression in said population of MLPC of at least one mRNA selected from the group consisting of CXCR4, FLT3, CD133, ICAM2, ITGAX, TFRC, KIT, IL6R, IL7R, ITGAM, FLT3, PDGFRB, SELE, SELL, TFRC, ITGAL, ITGB2, PECAM1, ITGA2B, ITGA3, ITGA4, ITGA6, ICAM1, CD24, CD34, CD44, CD45, CD58, CD68, CD33, CD37, CD38, TERT and POU5F.

2. The method of claim 1 , wherein expression of mRNA for CXCR4, FLT3, and CD133 is assessed.

3. The method of claim 1 , wherein expression of mRNA for TERT, KIT, and POU5F is assessed.

4. The method of claim 2 or 3 , wherein expression of mRNA for CD34 is assessed.

5. The method of claim 1 , wherein said MLPC are further negative for CD2, CD3, CD4, CD5, CD7, CD8, CD14, CD15, CD16, CD19, CD20, CD22, CD33, CD36, CD38, CD61, CD62E, CD133, glycophorin-A, stem cell factor, and HLA-DR.

6. The method of claim 1 , wherein expression of at least three mRNAs from said group is assessed.